


**FOR IMMEDIATE RELEASE**

## **ROSEAIld Secures Strategic Investment from Crewstone International to Advance AI-Powered Telepathology**

**Houston, TX, January 2026** – ROSEAIld, Inc today announced a strategic investment from Crewstone International, a leading global private equity and investment management firm. The partnership marks a major step forward in ROSEAIld’s mission to accelerate early cancer detection and improve clinical collaboration by integrating advanced AI solutions with conventional medical practices.



The investment will support ROSEAIld’s global growth, broaden the platform’s infrastructure, and fund the development of additional AI-driven diagnostic models designed to improve clinical workflows across healthcare systems globally. The platform will be expanding access to timely, accurate, expert pathology services for cancer screening, especially in underserved healthcare



systems and remote regions across the globe.

“We’re excited to secure Crewstone International’s participation as an investment partner,” said Joseph A. Rossi, Chief Executive Officer of ROSEAIId. “Their investment underscores confidence in our vision, making AI-powered digital pathology accessible to every pathologist and healthcare professional, anywhere. Our teamwork will help eliminate specialist shortages, drive faster, more accurate location-independent cancer diagnoses, saving lives on the road towards greater digital healthcare excellence, especially in underserved communities. ”

Crewstone is proud to partner with ROSEAIId, a company redefining how Digital AI Powered Pathology supports clinical and research-based decision-making,” said Izmir Mujab, Chief Executive Officer of Crewstone International. “Their AI platform represents the future of modern healthcare, and we look forward to supporting ROSEAIId’s growth as they scale their solutions and platforms globally.”

For more information, please visit [ROSEAIId](https://roseaid.com/)

### **About ROSEAIId**

**ROSEAIId, Inc** - is a health sciences AI based company with advanced technology in telepathology supporting clinical operations and research. Our Platform leverages AI-driven and machine learning models for early cancer detection and monitoring. ROSEAIId empowers healthcare professionals with solutions to make more informed decisions while streamlining clinical and scientific workflows. The firm continues to drive innovation in early cancer detection, delivering faster, more accurate solutions to meet healthcare challenges today and into the future.

### **About Crewstone International**

**Crewstone International** is a global private equity and investment management firm with a diversified portfolio spanning technology, healthcare and infrastructure. With over MYR 500 million in assets under management. Headquartered in Kuala Lumpur, Crewstone specializes in cross-border private equity, credit and fund strategies that deliver long-term value for institutional and government partners. Crewstone partners with innovative companies driving transformative change, offering strategic capital and expertise to scale growth and global impact.

For media inquiries, contact:

**Media Relations**

[Media@roseaid.com](mailto:Media@roseaid.com)

Follow us on [LinkedIn](https://www.linkedin.com/company/roseaid/) | Visit our Website: <https://roseaid.com/>